Marinus Pharmaceuticals Inc
(NASDAQ : MRNS)

( )
MRNS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
-6.66%17.512.0%$159.03m
ICPTIntercept Pharmaceuticals, Inc.
-4.60%109.8518.6%$127.35m
JAZZJazz Pharmaceuticals Plc
0.42%136.602.3%$113.61m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-4.07%168.836.3%$91.29m
SAGESAGE Therapeutics, Inc.
-0.80%156.728.8%$89.75m
HZNPHorizon Pharma plc
-3.83%26.847.3%$83.66m
PRGOPerrigo Co. Plc
-2.76%47.246.8%$66.07m
ICLRICON Plc
-2.83%132.884.1%$57.01m
UTHRUnited Therapeutics Corporation
-1.78%120.8014.3%$54.81m
MNKMallinckrodt Plc
-7.23%22.0821.0%$51.42m
PTLAPortola Pharmaceuticals, Inc.
-4.94%31.977.6%$42.48m
AERIAerie Pharmaceuticals, Inc.
-4.93%46.826.9%$40.04m
ENDPEndo International Plc
-4.91%8.338.9%$36.51m
MYOKMyoKardia, Inc.
-2.71%54.312.4%$35.96m
MDCOMedicines Company
-5.14%26.5821.8%$29.62m

Company Profile

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.